Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4061557
Max Phase: Preclinical
Molecular Formula: C56H89N9O11
Molecular Weight: 1064.38
Molecule Type: Small molecule
Associated Items:
ID: ALA4061557
Max Phase: Preclinical
Molecular Formula: C56H89N9O11
Molecular Weight: 1064.38
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: NC[C@H]1C[C@H](C(=O)N[C@H](CCc2ccccc2)C(=O)Nc2ccc3ccccc3c2)N(CCCCCCCCCCCCO[C@@H]2[C@@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H](N)C[C@H](N)[C@H]2O[C@H]2O[C@H](CN)[C@@H](O)C[C@H]2N)C1
Standard InChI: InChI=1S/C56H89N9O11/c57-30-35-26-43(54(71)64-42(23-20-34-16-10-9-11-17-34)53(70)63-38-22-21-36-18-12-13-19-37(36)27-38)65(32-35)24-14-7-5-3-1-2-4-6-8-15-25-72-52-50(75-55-41(61)29-44(67)45(31-58)73-55)39(59)28-40(60)51(52)76-56-49(69)47(62)48(68)46(33-66)74-56/h9-13,16-19,21-22,27,35,39-52,55-56,66-69H,1-8,14-15,20,23-26,28-33,57-62H2,(H,63,70)(H,64,71)/t35-,39+,40-,41-,42-,43-,44+,45-,46-,47+,48-,49-,50-,51+,52+,55-,56-/m1/s1
Standard InChI Key: WWRQNJVKBMPACY-GIQYZDEBSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1064.38 | Molecular Weight (Monoisotopic): 1063.6682 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Yang X, Goswami S, Gorityala BK, Domalaon R, Lyu Y, Kumar A, Zhanel GG, Schweizer F.. (2017) A Tobramycin Vector Enhances Synergy and Efficacy of Efflux Pump Inhibitors against Multidrug-Resistant Gram-Negative Bacteria., 60 (9): [PMID:28399372] [10.1021/acs.jmedchem.7b00156] |
Source(1):